SCHEMBL6405578

SCHEMBL6405578

O=C(O)[C@@H]1Cc2cc(-c3ccc(Br)cc3)ccc2O[C@@H]1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.36
FFAR1 O14842 4/20 0.35
TDP1 Q9NUW8 1/20 0.34
HRH3 Q9Y5N1 3/20 0.33
MMP3 P08254 1/20 0.32
MMP8 P22894 1/20 0.32
PIK3CA P42336 1/20 0.31
GLS O94925 1/20 0.31
DHODH Q02127 1/20 0.31
ALAD P13716 1/20 0.31
P2RY6 Q15077 1/20 0.30
PPARD Q03181 1/20 0.30
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6404784 1.00 FFAR4 (0.36) FFAR4FFAR1TDP1HRH3MMP3
SCHEMBL6405687 0.90 HRH3 (0.42) FFAR4FFAR1TDP1HRH3MMP3
SCHEMBL6403861 0.90 HRH3 (0.42) FFAR4FFAR1TDP1HRH3MMP3
SCHEMBL6410893 0.90 GLS (0.38) FFAR4FFAR1TDP1GLSP2RY6
SCHEMBL6412199 0.90 GLS (0.38) FFAR4FFAR1TDP1GLSP2RY6
SCHEMBL6406077 0.89 FFAR4 (0.38) FFAR4FFAR1TDP1HRH3
SCHEMBL6410937 0.89 FFAR4 (0.38) FFAR4FFAR1TDP1HRH3
SCHEMBL6411077 0.88 PTGS2 (0.38) FFAR4FFAR1TDP1HRH3
SCHEMBL6409748 0.88 PTGS2 (0.38) FFAR4FFAR1TDP1HRH3
SCHEMBL6410823 0.82 ADRA2A (0.38) TDP1P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050010050-A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders G.D. SEARLE & CO. (US) 2005-01-13 US disclosed
US-6822102-B2 COMPOUNDS SUCH AS (2S,3R)-6,8-DICHLORO-3,4-DIHYDRO-2-(TRIFLUOROMETHYL)-2H-1-BENZOPYRAN-3 -CARBOXYLIC ACID, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC, ANTICARCINOGENIC AGENTS OR ANALGESICS PHARMACIA CORPORATION 2004-11-23 US disclosed
EP-1274700-B1 DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS PHARMACIA CORP (US) 2004-11-17 EP disclosed
US-20030232844-A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders PHARMACIA CORPORATION 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050010050-A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders PTGS2, PTGES2, PTGER2 FFAR4 1283/4885FFAR1 1472/4885TDP1 1920/4885
US-20030232844-A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders PTGS2, PTGS1, PTGES2 FFAR4 1641/4885FFAR1 1180/4885TDP1 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.